【Generfull Biotech Co., Ltd.】Q1 2026 EPS -0.50 NTD

Key facts

  • 【Generfull Biotech Co., Ltd.】Q1 2026 EPS -0.50 NTD
  • Generfull Biotech Co., Ltd. announced its Q1 2026 financial results, with basic EPS of -0.50 NTD, operating revenue of 0.03 billion NTD, and net loss after tax of -0.76 billion NTD.
  • Source: PR Times
  • Date: March 1, 2026

Direct answer

Generfull Biotech Co., Ltd. announced its Q1 2026 financial results, with basic EPS of -0.50 NTD, operating revenue of 0.03 billion NTD, and net loss after tax of -0.76 billion NTD.

Citation
【Generfull Biotech Co., Ltd.】Q1 2026 EPS -0.50 NTD (March 1, 2026), PR Times
Source
PR Times
Date
March 1, 2026
Generfull Biotech Co., Ltd. announced its Q1 2026 financial results, with basic EPS of -0.50 NTD, operating revenue of 0.03 billion NTD, and net loss after tax of -0.76 billion NTD.
その他NQ 0/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: March 1, 2026 at 09:00
  • 🔍 Collected: May 12, 2026 at 08:00 (1727h 0m after Published)
  • 🤖 AI Analyzed: May 12, 2026 at 08:30 (29 min after Collected)
Company Code: 6885
Company Name: Generfull Biotech Co., Ltd.
Industry: Biotechnology and Medical Industry
Year/Quarter: Q1 2026
Basic Earnings Per Share: -0.50 NTD
Operating Revenue: 0.03 Billion NTD
Net Profit After Tax: -0.76 Billion NTD

FAQ

What are the key facts in this article?

Generfull Biotech Co., Ltd. announced its Q1 2026 financial results, with basic EPS of -0.50 NTD, operating revenue of 0.03 billion NTD, and net loss after tax of -0.76 billion NTD.

What is the direct answer?

Generfull Biotech Co., Ltd. announced its Q1 2026 financial results, with basic EPS of -0.50 NTD, operating revenue of 0.03 billion NTD, and net loss after tax of -0.76 billion NTD.

What is the source and date?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-6885-2026Q1 | March 1, 2026

Back to Newsroom (13)